sorafenib has been researched along with lestaurtinib in 15 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (lestaurtinib) | Trials (lestaurtinib) | Recent Studies (post-2010) (lestaurtinib) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 124 | 12 | 63 |
| Protein | Taxonomy | sorafenib (IC50) | lestaurtinib (IC50) |
|---|---|---|---|
| Tyrosine-protein kinase JAK2 | Homo sapiens (human) | 0.0009 | |
| Macrophage colony-stimulating factor 1 receptor | Homo sapiens (human) | 0.031 | |
| Receptor-type tyrosine-protein kinase FLT3 | Homo sapiens (human) | 0.0039 | |
| Dual specificity tyrosine-phosphorylation-regulated kinase 1A | Homo sapiens (human) | 0.012 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (13.33) | 29.6817 |
| 2010's | 9 (60.00) | 24.3611 |
| 2020's | 4 (26.67) | 2.80 |
| Authors | Studies |
|---|---|
| Armstrong, RC; Belli, B; Bhagwat, SS; Brigham, D; Chao, Q; Cramer, MD; Gardner, MF; Gunawardane, RN; James, J; Karaman, MW; Levis, M; Pallares, G; Patel, HK; Pratz, KW; Sprankle, KG; Zarrinkar, PP | 1 |
| Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP | 1 |
| Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
| Bharate, SB; Raghuvanshi, R | 1 |
| Abdel-Aziz, AK; Abouzid, KAM; Dokla, EME; McPhillie, MJ; Milik, SN; Minucci, S | 1 |
| Ehninger, G; Illmer, T | 1 |
| Levis, M; Murphy, KM; Pratz, KW; Rajkhowa, T; Sato, T; Stine, A | 1 |
| Burnett, A; Galkin, S; Knapper, S; Levis, M; Sato, T; Small, D; Smith, BD; White, P; Yang, X | 1 |
| Freeman, C; Giles, F; Swords, R | 1 |
| Bräuninger, A; Gattenlöhner, S; Holz, MS; Janning, A; Renné, C; Spieker, T | 1 |
| Hu, B; Mohty, M; Savani, BN; Vikas, P | 1 |
| Alvarado, Y; Andreeff, M; Borthakur, G; Cortes, JE; Estrov, Z; Garcia-Manero, G; Kantarjian, HM; Konopleva, M; Luthra, R; Ravandi, F | 1 |
| Brown, P; Levis, M; Li, L; Ma, H; Nguyen, B; Small, D; Williams, AB; Young, DJ | 1 |
| Antar, AI; Bazarbachi, A; Jabbour, E; Mohty, M; Otrock, ZK | 1 |
| Albors Ferreiro, M; Alonso Vence, N; Antelo Rodríguez, B; Bao Pérez, L; Bello López, JL; Cerchione, C; Cid López, M; Díaz Arias, JÁ; Ferreiro Ferro, R; González Pérez, MS; Martinelli, G; Mosquera Orgueira, A; Mosquera Torre, A; Peleteiro Raíndo, A; Pérez Encinas, MM | 1 |
5 review(s) available for sorafenib and lestaurtinib
| Article | Year |
|---|---|
FLT3 kinase inhibitors in the management of acute myeloid leukemia.
Topics: Benzenesulfonates; Carbazoles; Clinical Trials as Topic; fms-Like Tyrosine Kinase 3; Furans; Humans; Indoles; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Sorafenib; Staurosporine; Sunitinib | 2007 |
Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia.
Topics: Benzenesulfonates; Benzothiazoles; Carbazoles; CCAAT-Enhancer-Binding Protein-alpha; fms-Like Tyrosine Kinase 3; Furans; Humans; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Sorafenib; Staurosporine | 2012 |
Allogeneic stem cell transplantation and targeted therapy for FLT3/ITD+ acute myeloid leukemia: an update.
Topics: Carbazoles; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Furans; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Quinazolines; Sorafenib; Tandem Repeat Sequences; Transplantation, Homologous | 2014 |
FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions.
Topics: Aniline Compounds; Antineoplastic Agents; Benzimidazoles; Benzothiazoles; Carbazoles; DNA Methylation; Enzyme Inhibitors; fms-Like Tyrosine Kinase 3; Furans; Humans; Leukemia, Myeloid, Acute; Mutation; Neoplasm Recurrence, Local; Phenylurea Compounds; Piperidines; Prognosis; Pyrazines; Randomized Controlled Trials as Topic; Sorafenib; Staurosporine; Treatment Outcome | 2020 |
FLT3 inhibitors in the treatment of acute myeloid leukemia: current status and future perspectives.
Topics: Aniline Compounds; Antineoplastic Agents; Benzimidazoles; Benzothiazoles; Carbazoles; Drug Resistance, Multiple; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Forecasting; Furans; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Mutation; Phenylurea Compounds; Piperidines; Point Mutation; Protein Kinase Inhibitors; Pyrazines; Pyridazines; Recurrence; Sorafenib; Staurosporine | 2020 |
10 other study(ies) available for sorafenib and lestaurtinib
| Article | Year |
|---|---|
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).
Topics: Animals; Benzenesulfonates; Benzothiazoles; Bone Marrow; Carbazoles; Cell Line, Tumor; Cell Proliferation; Female; fms-Like Tyrosine Kinase 3; Furans; Humans; Leukemia, Myeloid, Acute; Mice; Mice, Nude; Mice, SCID; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Prognosis; Protein Interaction Mapping; Protein Kinase C; Protein Kinase Inhibitors; Pyridines; Quinazolines; Sorafenib; Staurosporine; Xenograft Model Antitumor Assays | 2009 |
Comprehensive analysis of kinase inhibitor selectivity.
Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity | 2011 |
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Approval; Drug Repositioning; High-Throughput Screening Assays; Humans; Protein Kinase Inhibitors; SARS-CoV-2; United States; United States Food and Drug Administration; Virus Diseases | 2022 |
Discovery of a benzimidazole-based dual FLT3/TrKA inhibitor targeting acute myeloid leukemia.
Topics: Antineoplastic Agents; Apoptosis; Benzimidazoles; Cell Line; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; fms-Like Tyrosine Kinase 3; Humans; Models, Molecular; Molecular Structure; Protein Kinase Inhibitors; Receptor, trkA; Structure-Activity Relationship | 2022 |
FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML.
Topics: Alleles; Antineoplastic Agents; Benzenesulfonates; Benzothiazoles; Carbazoles; Cell Death; Cell Line, Tumor; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Furans; Humans; Indazoles; Indoles; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Pyridines; Pyrroles; Sorafenib; Staurosporine; Sunitinib | 2010 |
FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo.
Topics: Antineoplastic Agents; Benzenesulfonates; Carbazoles; Cells, Cultured; Drug Antagonism; fms-Like Tyrosine Kinase 3; Furans; Humans; Indazoles; Inhibitory Concentration 50; Leukemia, Myeloid, Acute; Membrane Proteins; Multicenter Studies as Topic; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Sorafenib; Staurosporine; Treatment Outcome | 2011 |
Induction of endoplasmic reticulum stress by sorafenib and activation of NF-κB by lestaurtinib as a novel resistance mechanism in Hodgkin lymphoma cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carbazoles; Cell Line, Tumor; Drug Interactions; Drug Resistance, Neoplasm; Endoplasmic Reticulum Stress; Furans; Hodgkin Disease; Humans; NF-kappa B; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Reed-Sternberg Cells; Signal Transduction; Sorafenib | 2013 |
Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzothiazoles; Carbazoles; DNA Mutational Analysis; Female; fms-Like Tyrosine Kinase 3; Furans; Humans; Leukemia, Myeloid, Acute; Male; Medical Records; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Retrospective Studies; Sorafenib; Survival Analysis; Treatment Outcome | 2014 |
FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors.
Topics: Animals; Binding Sites; Blotting, Western; Carbazoles; Cell Line; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Furans; Gene Duplication; Humans; Mice, Inbred BALB C; Mutation; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Signal Transduction; Sorafenib; Tandem Repeat Sequences | 2017 |